Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunrest LifescienceNSE:SUNREST -1.69%42 Return-on-Tangible-Equity is 36.93% as of Mar. 2026, which is 30% above its 10-year median of 28.44. GuruFocus rates NSE:SUNREST with a GF Score™ of 42/100. The stock has 5 warning signs investors should review. Among 580 Healthcare Providers & Services companies, Sunrest Lifescience ranks better than 66.03% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sunrest Lifescience's annualized net income for the quarter that ended in Mar. 2026 was ₹67.7 Mil. Sunrest Lifescience's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹183.2 Mil. Therefore, Sunrest Lifescience's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 36.93%.
The historical rank and industry rank for Sunrest Lifescience's Return-on-Tangible-Equity or its related term are showing as below:
NSE:SUNREST'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 2.61 Med: 28.44 Max: 113.7
Current: 18.46
During the past 7 years, Sunrest Lifescience's highest Return-on-Tangible-Equity was 113.70%. The lowest was 2.61%. And the median was 28.44%.
NSE:SUNREST's Return-on-Tangible-Equity is ranked better than 66.03% of 580
companies
in the Healthcare Providers & Services industry
Industry Median: 10.085
vs NSE:SUNREST: 18.46
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sunrest Lifescience Return-on-Tangible-Equity Related Terms
Sunrest Lifescience Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sunrest Lifescience's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Sunrest Lifescience's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunrest Lifescience Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sunrest Lifescience's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sunrest Lifescience's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 36.93% mean?
Sunrest Lifescience (NSE:SUNREST) has a Return-on-Tangible-Equity of 36.93% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sunrest Lifescience and its competitors. This is 30% above median its historical median of 28.44. Over the past decade, Sunrest Lifescience's Return-on-Tangible-Equity has ranged from 2.61 to 113.70. According to the industry distribution chart, Sunrest Lifescience ranks #197 out of 580 companies in the Healthcare Providers & Services industry, placing it in the top 34%.
Is Sunrest Lifescience's Return-on-Tangible-Equity too high?
Sunrest Lifescience's current Return-on-Tangible-Equity of 36.93% is 30% above median its 10-year median of 28.44. Over the past 10 years, this metric has ranged from a low of 2.61 to a high of 113.70. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.09. Sunrest Lifescience's value of 36.93% is 266.2% above this industry median. Based on the distribution chart, Sunrest Lifescience ranks #197 out of 580 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Sunrest Lifescience has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Sunrest Lifescience's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Sunrest Lifescience ranks #197 out of 580 companies for Return-on-Tangible-Equity. This puts Sunrest Lifescience in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.09. Sunrest Lifescience's value of 36.93% is 266.2% above this benchmark. Historically, Sunrest Lifescience's own Return-on-Tangible-Equity has ranged from 2.61 to 113.70 over the past decade. While the company's 10-year median is 28.44 vs. the industry median of 10.09, Sunrest Lifescience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.09, based on 580 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunrest Lifescience's current Return-on-Tangible-Equity of 36.93% is 266.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sunrest Lifescience and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunrest Lifescience's current Return-on-Tangible-Equity is 36.93%, which is 30% above median its own 10-year median of 28.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunrest Lifescience stock overvalued right now?
Sunrest Lifescience (NSE:SUNREST) has a current Return-on-Tangible-Equity of 36.93%. The current Return-on-Tangible-Equity is 36.93%, which is 30% above median its 10-year median of 28.44 and 266.2% above the Healthcare Providers & Services industry median of 10.09. Sunrest Lifescience's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sunrest Lifescience (NSE:SUNREST), the current Return-on-Tangible-Equity is 36.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunrest Lifescience Ltd is engaged in the trading business of pharmaceutical products, including capsules, tablets, syrups, ointments, gels, mouthwash, and toothpaste on a wholesale and retail basis. Its product portfolio covers categories such as anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, dental care, anti-inflammatory, nutraceuticals, and more. The company works with a network of suppliers and super suppliers, distributing products to chemists, hospitals, and dispensaries across multiple Indian states. Sunrest relies on both in-house manufacturing through its group company Trilend Pharmaceuticals and third-party manufacturers, emphasizing quality control and regulatory compliance.
42GF Score
Get the complete analysis for NSE:SUNREST
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUNREST has been successfully added to your 
